JPWO2020086730A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020086730A5 JPWO2020086730A5 JP2021521976A JP2021521976A JPWO2020086730A5 JP WO2020086730 A5 JPWO2020086730 A5 JP WO2020086730A5 JP 2021521976 A JP2021521976 A JP 2021521976A JP 2021521976 A JP2021521976 A JP 2021521976A JP WO2020086730 A5 JPWO2020086730 A5 JP WO2020086730A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- amino acid
- acid sequence
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 60
- 102100034111 Activin receptor type-1 Human genes 0.000 claims 42
- 101000799140 Homo sapiens Activin receptor type-1 Proteins 0.000 claims 42
- 239000012634 fragment Substances 0.000 claims 42
- 150000001413 amino acids Chemical class 0.000 claims 19
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 239000013604 expression vector Substances 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
- 208000034970 Heterotopic Ossification Diseases 0.000 claims 1
- 208000003452 Multiple Hereditary Exostoses Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 230000009787 cardiac fibrosis Effects 0.000 claims 1
- 208000028919 diffuse intrinsic pontine glioma Diseases 0.000 claims 1
- 208000026144 diffuse midline glioma, H3 K27M-mutant Diseases 0.000 claims 1
- 230000007941 heterotopic ossification Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024102779A JP2024114820A (ja) | 2018-10-23 | 2024-06-26 | Ａｌｋ２抗体及びその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862749463P | 2018-10-23 | 2018-10-23 | |
| US62/749,463 | 2018-10-23 | ||
| PCT/US2019/057679 WO2020086730A1 (en) | 2018-10-23 | 2019-10-23 | Alk2 antibodies and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024102779A Division JP2024114820A (ja) | 2018-10-23 | 2024-06-26 | Ａｌｋ２抗体及びその使用方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022505585A JP2022505585A (ja) | 2022-01-14 |
| JPWO2020086730A5 true JPWO2020086730A5 (https=) | 2022-10-18 |
| JP2022505585A5 JP2022505585A5 (https=) | 2022-10-18 |
| JP7512272B2 JP7512272B2 (ja) | 2024-07-08 |
Family
ID=70331231
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021521976A Active JP7512272B2 (ja) | 2018-10-23 | 2019-10-23 | Ａｌｋ２抗体及びその使用方法 |
| JP2024102779A Pending JP2024114820A (ja) | 2018-10-23 | 2024-06-26 | Ａｌｋ２抗体及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024102779A Pending JP2024114820A (ja) | 2018-10-23 | 2024-06-26 | Ａｌｋ２抗体及びその使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12331124B2 (https=) |
| EP (1) | EP3870613A4 (https=) |
| JP (2) | JP7512272B2 (https=) |
| KR (1) | KR102919834B1 (https=) |
| CN (2) | CN118955715A (https=) |
| AU (1) | AU2019364415A1 (https=) |
| BR (1) | BR112021007660A2 (https=) |
| CA (1) | CA3116900A1 (https=) |
| IL (1) | IL282424A (https=) |
| WO (1) | WO2020086730A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7504880B2 (ja) | 2018-10-26 | 2024-06-24 | ケロス セラピューティクス インコーポレイテッド | Ａｌｋ２阻害剤の結晶形 |
| CN114761013A (zh) | 2019-09-27 | 2022-07-15 | 迪斯克医药公司 | 治疗骨髓纤维化和相关病症的方法 |
| CN115362175A (zh) * | 2020-02-11 | 2022-11-18 | 瑞泽恩制药公司 | 抗acvr1抗体及其用途 |
| US12508262B2 (en) | 2020-04-30 | 2025-12-30 | Keros Therapeutics, Inc. | Methods of using ALK2 inhibitors |
| WO2021231798A1 (en) | 2020-05-13 | 2021-11-18 | Disc Medicine, Inc. | Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis |
| WO2022098812A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating iron overload |
| WO2022240948A1 (en) * | 2021-05-11 | 2022-11-17 | Keros Therapeutics, Inc. | Methods of using alk2 and alk3 antibodies |
| WO2023081212A1 (en) * | 2021-11-02 | 2023-05-11 | Keros Therapeutics, Inc. | Methods of using alk2 inhibitors |
| US20240150474A1 (en) * | 2022-10-27 | 2024-05-09 | Regeneron Pharmaceuticals, Inc. | Anti-acvri antibodies and their use in the treatment of trauma-induced heterotopic ossification |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008501781A (ja) * | 2004-06-09 | 2008-01-24 | テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド | 細胞の選択的アポトーシスのための抗体 |
| MX2009002418A (es) | 2006-09-05 | 2009-04-23 | Medarex Inc | Anticuerpos para las proteinas morfogenicas oseas y receptores de estas y metodos para su uso. |
| CN102548617B (zh) | 2009-03-30 | 2017-11-07 | 阿塞勒隆制药公司 | Bmp‑alk3拮抗剂和促进骨生长的用途 |
| US20130089560A1 (en) | 2010-03-17 | 2013-04-11 | Oncomed Pharmaceuticals Inc | Bone morphogenetic protein receptor binding agents and methods of their use |
| WO2012065059A2 (en) | 2010-11-12 | 2012-05-18 | The General Hospital Corporation | Treatment of atherosclerosis with bmp-alk3 antagonists |
| WO2015152183A1 (ja) | 2014-03-31 | 2015-10-08 | 大日本住友製薬株式会社 | 進行性骨化性線維異形成症の予防剤及び治療剤 |
| US20160075772A1 (en) | 2014-09-12 | 2016-03-17 | Regeneron Pharmaceuticals, Inc. | Treatment of Fibrodysplasia Ossificans Progressiva |
| BR112017015661A2 (pt) * | 2015-01-30 | 2018-03-20 | Saitama Medical University | anticorpo anti-alk2 |
| US10620204B2 (en) * | 2015-03-26 | 2020-04-14 | Vanderbilt University | Antibody-mediated neutralization of Ebola viruses |
| US12428484B2 (en) | 2018-12-06 | 2025-09-30 | Alexion Pharmaceuticals, Inc. | Anti-ALK2 antibodies and uses thereof |
| CN115362175A (zh) | 2020-02-11 | 2022-11-18 | 瑞泽恩制药公司 | 抗acvr1抗体及其用途 |
| JP2023530316A (ja) | 2020-06-16 | 2023-07-14 | インサイト・コーポレイション | 貧血の治療のためのａｌｋ２阻害剤 |
| WO2022098812A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating iron overload |
| WO2022098821A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating lymphopenia |
| WO2022099166A1 (en) | 2020-11-09 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating cardiovascular-related disease |
| WO2022240948A1 (en) | 2021-05-11 | 2022-11-17 | Keros Therapeutics, Inc. | Methods of using alk2 and alk3 antibodies |
-
2019
- 2019-10-23 CN CN202411099364.XA patent/CN118955715A/zh active Pending
- 2019-10-23 EP EP19877108.1A patent/EP3870613A4/en active Pending
- 2019-10-23 BR BR112021007660-3A patent/BR112021007660A2/pt unknown
- 2019-10-23 JP JP2021521976A patent/JP7512272B2/ja active Active
- 2019-10-23 CN CN201980085459.7A patent/CN113366019B/zh active Active
- 2019-10-23 CA CA3116900A patent/CA3116900A1/en active Pending
- 2019-10-23 WO PCT/US2019/057679 patent/WO2020086730A1/en not_active Ceased
- 2019-10-23 KR KR1020217015329A patent/KR102919834B1/ko active Active
- 2019-10-23 AU AU2019364415A patent/AU2019364415A1/en active Pending
-
2021
- 2021-04-19 IL IL282424A patent/IL282424A/en unknown
- 2021-04-22 US US17/237,240 patent/US12331124B2/en active Active
-
2024
- 2024-06-26 JP JP2024102779A patent/JP2024114820A/ja active Pending
-
2025
- 2025-05-14 US US19/207,888 patent/US20250270333A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5047996B2 (ja) | 糸球体腎炎および他の炎症性疾患の治療のための組成物および方法 | |
| JP6591964B2 (ja) | Ｉｃｏｓｌへの治療上の標的特異的ｖｎａｒドメインの単離 | |
| JP2022105138A5 (https=) | ||
| JP2007514419A5 (https=) | ||
| JP2021524267A5 (https=) | ||
| JP2019511911A5 (https=) | ||
| JP2025528797A (ja) | トランスフェリン受容体結合タンパク質及びコンジュゲート | |
| JPWO2020069028A5 (https=) | ||
| JP2011212022A (ja) | Ｄｋｋ−１に対する抗体 | |
| JP2010511388A5 (https=) | ||
| CN101842388B (zh) | 针对β淀粉样肽的人源化抗体 | |
| JP2010509931A5 (https=) | ||
| JP2020505919A5 (https=) | ||
| JP2022126804A5 (https=) | ||
| JPWO2020059847A5 (https=) | ||
| JP2021520393A5 (https=) | ||
| JPWO2020086730A5 (https=) | ||
| WO2021012195A1 (zh) | 可结合sftsv的纳米抗体及其应用 | |
| JPWO2020011966A5 (https=) | ||
| JP2021515037A5 (https=) | ||
| JP2024016201A5 (https=) | ||
| JP2006521088A5 (https=) | ||
| CA2283540A1 (en) | Anti-fas antibodies | |
| JP2009529915A5 (https=) | ||
| JP2008507253A5 (https=) |